$ATNF
180 Life Sciences Corp.

2023 Q2 Form 10-Q Financial Statement

#000121390023039786 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.762M $4.009M $2.974M
YoY Change -31.26% 34.78% 15.23%
% of Gross Profit
Research & Development $789.4K $578.3K $706.7K
YoY Change 56.73% -18.16% 92.58%
% of Gross Profit
Depreciation & Amortization $28.55K $21.77K $26.46K
YoY Change -22.75% -17.72% -7.71%
% of Gross Profit
Operating Expenses $3.683M $4.804M $3.681M
YoY Change -18.55% 30.5% 24.85%
Operating Profit -$3.683M -$4.804M -$3.681M
YoY Change -18.55% 30.5%
Interest Expense $11.61K $56.46K $5.227M
YoY Change -99.84% -98.92% -139.14%
% of Operating Profit
Other Income/Expense, Net $2.811K $41.77K $17.52K
YoY Change -116.04% 138.4% -102.86%
Pretax Income -$3.680M -$4.762M $1.564M
YoY Change -225.21% -404.54% -109.65%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.680M -$4.762M $1.564M
YoY Change -225.21% -404.54% -109.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70 -$1.27 $0.92
Diluted Earnings Per Share -$0.70 -$1.27 $45.90K
COMMON SHARES
Basic Shares Outstanding 5.318M shares 3.747M shares 1.703M shares
Diluted Shares Outstanding 5.231M shares 3.747M shares 1.703M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.009M $2.646M $5.669M
YoY Change 23.59% -53.32% -6.34%
Cash & Equivalents $2.009M $2.646M $5.669M
Short-Term Investments
Other Short-Term Assets $836.3K $1.193M $3.288M
YoY Change -66.6% -63.72% 69.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.934M $4.196M $8.957M
YoY Change -36.86% -53.15% 7.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $1.669M $1.663M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.73M $10.73M $50.72M
YoY Change -77.97% -78.85% -2.11%
TOTAL ASSETS
Total Short-Term Assets $2.934M $4.196M $8.957M
Total Long-Term Assets $10.73M $10.73M $50.72M
Total Assets $13.67M $14.92M $59.68M
YoY Change -74.39% -74.99% -0.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $837.0K $1.208M $1.039M
YoY Change -47.38% 16.27% -74.91%
Accrued Expenses $2.500M $2.821M $2.665M
YoY Change 26.03% 5.85% -21.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $86.03K
YoY Change -100.0% -100.0% -92.18%
Long-Term Debt Due $588.2K $842.2K $1.296M
YoY Change -26.83% -35.04% 113.83%
Total Short-Term Liabilities $4.273M $5.122M $15.08M
YoY Change -38.66% -66.03% -55.16%
LONG-TERM LIABILITIES
Long-Term Debt $26.31K $28.73K $43.61K
YoY Change -29.54% -34.12% -59.61%
Other Long-Term Liabilities $31.08K
YoY Change
Total Long-Term Liabilities $26.31K $28.73K $74.69K
YoY Change -29.54% -61.53% -30.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.273M $5.122M $15.08M
Total Long-Term Liabilities $26.31K $28.73K $74.69K
Total Liabilities $6.951M $7.783M $18.77M
YoY Change -34.21% -58.54% -49.81%
SHAREHOLDERS EQUITY
Retained Earnings -$115.9M -$112.2M
YoY Change
Common Stock $532.00 $375.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.716M $7.140M $40.90M
YoY Change
Total Liabilities & Shareholders Equity $13.67M $14.92M $59.68M
YoY Change -74.39% -74.99% -0.72%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.680M -$4.762M $1.564M
YoY Change -225.21% -404.54% -109.65%
Depreciation, Depletion And Amortization $28.55K $21.77K $26.46K
YoY Change -22.75% -17.72% -7.71%
Cash From Operating Activities -$3.117M -$3.870M -$2.073M
YoY Change -11.74% 86.69% -67.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.462M -469.8K -515.4K
YoY Change -598.09% -8.85% -104.97%
NET CHANGE
Cash From Operating Activities -3.117M -$3.870M -2.073M
Cash From Investing Activities
Cash From Financing Activities 2.462M -469.8K -515.4K
Net Change In Cash -654.6K -$4.324M -2.588M
YoY Change -83.74% 67.05% -164.19%
FREE CASH FLOW
Cash From Operating Activities -$3.117M -$3.870M -$2.073M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
180 Life Sciences Corp.
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38105
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1890354
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 El Camino Real Bldg. 4
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
CY2023Q1 dei City Area Code
CityAreaCode
(650)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
507-0669
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5317586 shares
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2646184 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6970110 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1550215 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1958280 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
4196399 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8928390 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1663032 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1658858 usd
CY2023Q1 atnf Inprocess Research And Development
InprocessResearchAndDevelopment
9063000 usd
CY2022Q4 atnf Inprocess Research And Development
InprocessResearchAndDevelopment
9063000 usd
CY2023Q1 us-gaap Assets
Assets
14922431 usd
CY2022Q4 us-gaap Assets
Assets
19650248 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1208110 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1801210 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2821013 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2284516 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
228581 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
188159 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
842202 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1308516 usd
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
22058 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
75381 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5121964 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5657782 usd
CY2023Q1 atnf Loans Payable Non Current Portion
LoansPayableNonCurrentPortion
28732 usd
CY2022Q4 atnf Loans Payable Non Current Portion
LoansPayableNonCurrentPortion
31189 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2631811 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2617359 usd
CY2023Q1 us-gaap Liabilities
Liabilities
7782507 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8306330 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3746906 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3746906 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3746906 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3746906 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
375 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
375 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122195032 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637611 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2884860 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2885523 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112170623 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107408545 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7139924 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11343918 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14922431 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19650248 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
578309 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
658939 usd
CY2023Q1 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
216684 usd
CY2022Q1 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
47718 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4008852 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2969151 usd
CY2022Q1 atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
5261 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4803845 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3681069 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4803845 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3681069 usd
CY2023Q1 atnf Interest Expense Related Parties
InterestExpenseRelatedParties
11556 usd
CY2022Q1 atnf Interest Expense Related Parties
InterestExpenseRelatedParties
7414 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4562 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-53323 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5230114 usd
CY2022Q1 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
-17520 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
41767 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5244782 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4762078 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1563713 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4762078 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1563713 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
663 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-728081 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4761415 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
835632 usd
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.27
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.92
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.27
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.92
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3747145 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1702997 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3747145 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1703439 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11343918 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
557421 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4762078 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
663 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7139924 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
39322695 usd
CY2022Q1 atnf Shares Issued In Connection With The Repayment Of Related Party Loans And Convertible Notes
SharesIssuedInConnectionWithTheRepaymentOfRelatedPartyLoansAndConvertibleNotes
149718 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
596467 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1563713 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-728081 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40904512 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4762078 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1563713 usd
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
149718 usd
CY2023Q1 atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
-557421 usd
CY2022Q1 atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
-596467 usd
CY2023Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
21772 usd
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
26462 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
22332 usd
CY2023Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-53323 usd
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-5230114 usd
CY2022Q1 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
-17520 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-424913 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
325057 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-621861 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
454982 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
526367 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
662880 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
36898 usd
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
19270 usd
CY2022Q1 atnf Accrued Issuable Equitys
AccruedIssuableEquitys
-48600 usd
CY2023Q1 atnf Total Adjustments
TotalAdjustments
892187 usd
CY2022Q1 atnf Total Adjustments
TotalAdjustments
-3636644 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3869891 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2072931 usd
CY2023Q1 atnf Proceeds From Convertible Notes Payable
ProceedsFromConvertibleNotesPayable
-469810 usd
CY2022Q1 atnf Proceeds From Convertible Notes Payable
ProceedsFromConvertibleNotesPayable
-515419 usd
CY2023Q1 atnf Deemed Dividend Beneficial Conversion Feature On Series A Convertible Preferred Stock
DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock
-469810 usd
CY2022Q1 atnf Deemed Dividend Beneficial Conversion Feature On Series A Convertible Preferred Stock
DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock
-515419 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15775 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32757 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4323926 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2555593 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6970110 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8224508 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2646184 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5668915 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
7265 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2853 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp., formerly known as KBL Merger Corp. IV (“180LS”, or together with its subsidiaries, the “Company”), was a blank check company organized under the laws of the State of Delaware on September 7, 2016. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On November 6, 2020, a business combination was consummated following a special meeting of stockholders, where the stockholders of the Company considered and approved, among other matters, a proposal to adopt a Business Combination Agreement. Pursuant to the Business Combination Agreement, KBL Merger Sub, Inc. merged with 180 Life Corp. (f/k/a 180 Life Sciences Corp.) (“<span style="text-decoration:underline">180</span>”), with 180 continuing as the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Business Combination”). References to “KBL” refer to the Company prior to the November 6, 2020 Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis and other inflammatory diseases, where anti-TNF therapy will provide a clear benefit to patients, by employing innovative research, and, where appropriate, combination therapy. We have three product development platforms:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrosis and anti-tumor necrosis factor (“TNF”);</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drugs which are derivatives of cannabidiol (“CBD”); and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alpha 7 nicotinic acetylcholine receptor (“α7nAChR”).</span></td></tr> </table>
CY2023Q1 atnf Accumulated Deficit
AccumulatedDeficit
112170623 usd
CY2023Q1 atnf Working Capital Deficit
WorkingCapitalDeficit
925565 usd
CY2023Q1 atnf Net Income Loss Operating Activities
NetIncomeLossOperatingActivities
4762078 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
3869891 usd
CY2023Q1 atnf Aggregate Shares
AggregateShares
400000 shares
CY2023Q1 us-gaap Demutualization By Insurance Entity Securities Issued Gross Cash Proceeds
DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds
3000000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3747145 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1702997 shares
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
442 usd
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
442 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3747145 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1703439 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the collectability of an insurance claims receivable, the fair value of financial instruments warrants, options and equity shares, the valuation of stock-based compensation, and the estimates and assumptions related to impairment analysis of in-process research and development assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and may cause actual results to differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p>
CY2023Q1 atnf Assets And Liabilities Exchange Rates Description
AssetsAndLiabilitiesExchangeRatesDescription
The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2345 and 1.2098 GBP to 1 US dollar, each as of March 31, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2138 and 1.3413 GBP to 1 US dollar for each of the three months ended March 31, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ equity as a component of accumulated other comprehensive income.
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
663 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-728081 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1117 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-142 usd
CY2022 atnf Carrying Amount
CarryingAmount
12405084 usd
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
9063000 usd
CY2022 atnf Assets Impaired
AssetsImpaired
3342084 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
9063000 usd
CY2023Q1 atnf Carrying Amount
CarryingAmount
9063000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4762078 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1563713 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.92
CY2023Q1 atnf Options
Options
152045 shares
CY2022Q1 atnf Options
Options
134550 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3435728 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
557696 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3587773 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
692246 shares
CY2023Q1 atnf Litigation Receivable
LitigationReceivable
754217 usd
CY2022 atnf Litigation Receivable
LitigationReceivable
1027292 usd
CY2023Q1 atnf Research And Development Expense Tax Credit Receivable
ResearchAndDevelopmentExpenseTaxCreditReceivable
322129 usd
CY2022 atnf Research And Development Expense Tax Credit Receivable
ResearchAndDevelopmentExpenseTaxCreditReceivable
546563 usd
CY2023Q1 atnf Professional Feeses
ProfessionalFeeses
438501 usd
CY2022 atnf Professional Feeses
ProfessionalFeeses
310017 usd
CY2023Q1 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
9734 usd
CY2022Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
48774 usd
CY2023Q1 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
25634 usd
CY2022Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
25634 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1550215 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1958280 usd
CY2023Q1 atnf Consulting Fees
ConsultingFees
517489 usd
CY2022 atnf Consulting Fees
ConsultingFees
531829 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
3945 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1305521 usd
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1558024 usd
CY2023Q1 atnf Research And Development Fees
ResearchAndDevelopmentFees
165395 usd
CY2022 atnf Research And Development Fees
ResearchAndDevelopmentFees
22023 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
56457 usd
CY2022 us-gaap Interest Expense
InterestExpense
36422 usd
CY2023Q1 atnf Other Accrued Liabilities
OtherAccruedLiabilities
-11595 usd
CY2022 atnf Other Accrued Liabilities
OtherAccruedLiabilities
-7018 usd
CY2023Q1 atnf Accrued Liabilities
AccruedLiabilities
2821013 usd
CY2022 atnf Accrued Liabilities
AccruedLiabilities
2284516 usd
CY2023Q1 atnf Related Party Expenses
RelatedPartyExpenses
228581 usd
CY2022 atnf Related Party Expenses
RelatedPartyExpenses
188159 usd
CY2023Q1 atnf Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Price
SharePrice
1.8
CY2022 atnf Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Price
SharePrice
3.39
CY2021Q1 atnf Beneficial Ownership
BeneficialOwnership
0.0499 pure
CY2023Q1 atnf Warrant Revalued
WarrantRevalued
72 usd
CY2023Q1 us-gaap Credit Risk Derivative Liabilities At Fair Value
CreditRiskDerivativeLiabilitiesAtFairValue
141.4 usd
CY2023Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
0 usd
CY2023Q1 atnf Outstanding Warrants Percentage
OutstandingWarrantsPercentage
0.15 pure
CY2022Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
1339705 usd
CY2023Q1 atnf Adjustments Amount
AdjustmentsAmount
-469810 usd
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
1039 usd
CY2023Q1 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
870934 usd
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
1308516 usd
CY2023Q1 us-gaap Notes And Loans Payable
NotesAndLoansPayable
842202 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
31189 usd
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
28732 usd
CY2023Q1 us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
3018 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
11556 usd
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
7414 usd
CY2023Q1 us-gaap Other Loans Payable
OtherLoansPayable
0 usd
CY2022Q1 us-gaap Other Loans Payable
OtherLoansPayable
4562 usd
CY2023Q1 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
1227 usd
CY2022 atnf Interest Expense On Loans Payable Description
InterestExpenseOnLoansPayableDescription
As of December 31, 2022, the Company had accrued interest and accrued interest — related parties associated with loans payable of $36,422 and $16,770, respectively. See Note 10 — Related Parties for additional details.
CY2021Q3 us-gaap Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate
ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate
11286570 usd
CY2022Q1 atnf Debt Principal Amount
DebtPrincipalAmount
371178 usd
CY2022Q1 atnf Debt Additional Amount
DebtAdditionalAmount
300000 usd
CY2023Q1 us-gaap Interest Receivable
InterestReceivable
6776686 usd
CY2023Q1 atnf Commitments Combined Amount
CommitmentsCombinedAmount
4395000 cad
CY2023Q1 atnf Commitments Combined Amount
CommitmentsCombinedAmount
3248696 usd
CY2023Q1 atnf Additional Sum Of Amount
AdditionalSumOfAmount
2721036 usd
CY2021Q3 atnf Settlement Paying Amount
SettlementPayingAmount
2000000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 atnf Restricted Shares
RestrictedShares
600 shares
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
8100 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
275 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
81
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
100 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
81
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
120 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
81
CY2023Q1 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
9720 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162956 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
84.63
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2023Q1 atnf Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
10911 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
152045 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
85.03
CY2023Q1 atnf Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
101759 shares
CY2023Q1 atnf Weighted Average Exercise Price Exercisable Ending
WeightedAverageExercisePriceExercisableEnding
84.34
CY2023Q1 atnf Weighted Average Remaining Term1 Exercisable Ending
WeightedAverageRemainingTerm1ExercisableEnding
P7Y10M24D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
152045 shares
CY2023Q1 atnf Stock Options Exercisable Weighted Average Remainings Life In Years
StockOptionsExercisableWeightedAverageRemainingsLifeInYears
P7Y10M24D
CY2023Q1 atnf Stock Options Exercisable Number Of Share
StockOptionsExercisableNumberOfShare
101759 shares
CY2023Q1 us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
557421 usd
CY2023Q1 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
596467 usd
CY2023Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
514696 usd
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
81771 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3435728 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.94
CY2022Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y1M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3435728 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.94
CY2022Q1 atnf Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2
P4Y9M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3435728 shares
CY2022Q1 atnf Weighted Average Exercise Price Exercisable Ending
WeightedAverageExercisePriceExercisableEnding
33.94
CY2022Q1 atnf Weighted Average Remaining Term1 Exercisable Ending
WeightedAverageRemainingTerm1ExercisableEnding
P4Y9M18D
CY2022Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3435728 shares
CY2022Q1 atnf Stock Options Exercisable Weighted Average Remainings Life In Years
StockOptionsExercisableWeightedAverageRemainingsLifeInYears
P4Y9M18D
CY2022Q1 atnf Stock Options Exercisable Number Of Share
StockOptionsExercisableNumberOfShare
3435728 shares
CY2023Q1 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
228581 usd
CY2022Q1 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
188159 usd
CY2023Q1 atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
216684 usd
CY2022Q1 atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
47718 usd
CY2022Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
5261 usd
CY2023Q1 atnf Investors
Investors
0.05 pure
CY2023Q1 us-gaap Goodwill
Goodwill
usd
CY2022Q4 us-gaap Goodwill
Goodwill
usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
CY2023Q1 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
usd
CY2023Q1 atnf Accrued Issuable Equitys
AccruedIssuableEquitys
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1 atnf Weighted Average Remaining Term1 Granted
WeightedAverageRemainingTerm1Granted
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1 atnf Weighted Average Remaining Term1 Exercised
WeightedAverageRemainingTerm1Exercised
CY2023Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised
usd
CY2023Q1 atnf Number Of Options Expired
NumberOfOptionsExpired
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1 atnf Weighted Average Remaining Term1 Expired
WeightedAverageRemainingTerm1Expired
CY2023Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired
usd
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1 atnf Weighted Average Remaining Term1 Forfeited
WeightedAverageRemainingTerm1Forfeited
CY2023Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2023Q1 atnf Intrinsic Value Exercisable Ending
IntrinsicValueExercisableEnding
usd
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q1 atnf Weighted Average Remaining Termin Years Issued
WeightedAverageRemainingTerminYearsIssued
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
usd
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q1 atnf Weighted Average Remaining Term1 Exercised
WeightedAverageRemainingTerm1Exercised
CY2022Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised
usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q1 atnf Weighted Average Remaining Termin Years Cancelled
WeightedAverageRemainingTerminYearsCancelled
CY2022Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled
usd
CY2022Q1 atnf Number Of Options Expired
NumberOfOptionsExpired
shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q1 atnf Weighted Average Remaining Term1 Expired
WeightedAverageRemainingTerm1Expired
CY2022Q1 atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired
usd
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2022Q1 atnf Intrinsic Value Exercisable Ending
IntrinsicValueExercisableEnding
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001690080

Files In Submission

Name View Source Status
0001213900-23-039786-index-headers.html Edgar Link pending
0001213900-23-039786-index.html Edgar Link pending
0001213900-23-039786.txt Edgar Link pending
0001213900-23-039786-xbrl.zip Edgar Link pending
atnf-20230331.xsd Edgar Link pending
atnf-20230331_cal.xml Edgar Link unprocessable
atnf-20230331_def.xml Edgar Link unprocessable
atnf-20230331_pre.xml Edgar Link unprocessable
f10q0323ex10-11_180lifesci.htm Edgar Link pending
f10q0323ex10-12_180lifesci.htm Edgar Link pending
f10q0323ex31-1_180lifesci.htm Edgar Link pending
f10q0323ex31-2_180lifesci.htm Edgar Link pending
f10q0323ex32-1_180lifesci.htm Edgar Link pending
f10q0323ex32-2_180lifesci.htm Edgar Link pending
f10q0323_180lifescien.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
f10q0323_180lifescien_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atnf-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable